Logo
x

Search category

Subscribe Now

locally advanced

Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Expanded Indication in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma

Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Expanded Indication in Patients with Locally Advanced Cutaneou...

  • July 6, 2021
Merck KGaA and Pfizer's Bavencio (avelumab) Receive the US FDA's Approval as a 1L Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

Merck KGaA and Pfizer's Bavencio (avelumab) Receive the US FDA's Approval as a 1L Treatment for Locally Advanced or Metastatic Uro...

  • July 1, 2020
Merck KGaA and Pfizer Report EMA's Validation for Bavencio (avelumab) as a 1L Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

Merck KGaA and Pfizer Report EMA's Validation for Bavencio (avelumab) as a 1L Treatment for Locally Advanced or Metastatic Urothel...

  • June 22, 2020
Samsung Bioepis Reports Results of Ontruzant (biosimilar- trastuzumab) in P-III Follow-up Study (SB3-G31-BC-E) for Early or Locally Advanced HER2-Positive Breast Cancer

Samsung Bioepis Reports Results of Ontruzant (biosimilar- trastuzumab) in P-III Follow-up Study (SB3-G31-BC-E) for Early or Locall...

  • May 15, 2020
EMD Serono and Pfizer's Bavencio (avelumab) Receive the US FDA's Breakthrough Therapy Designation as 1L Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

EMD Serono and Pfizer's Bavencio (avelumab) Receive the US FDA's Breakthrough Therapy Designation as 1L Maintenance Treatment of L...

  • April 9, 2020
Merck KGaA and Pfizer Report Results of Bavencio (avelumab) in P-III JAVELIN Bladder 100 Study for Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Merck KGaA and Pfizer Report Results of Bavencio (avelumab) in P-III JAVELIN Bladder 100 Study for Patients with Locally Advanced...

  • January 7, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.